title: [A case of organ sparing surgery for metachronous bilateral testicular tumor with maintaining testicular function].
abstract: A 28-year-old man, who had undergone right orchiectomy and prophylactic irradiation for stage I seminoma 6 years ago, developed left testicular tumor. Since the secondary tumor was localized in the lower pole of the testis, partial orchiectomy was performed with an attempt to preserve the testicular function. The pathological finding of the surgical specimen was a mixed type testicular tumor consisting of seminoma, embryonal carcinoma and teratoma elements. Postoperative chemotherapy with 3 courses of BEP regimen resulted in azoospermia, but the impaired spermatogenesis recovered to a normal range within 18 months with no evidence of tumor recurrence and his wife delivered a healthy baby 2 years later. For the synchronous or metachronous bilateral testicular tumors, the combination of organ sparing surgery and chemotherapy could be a treatment of choice.
authors.affiliation: Department of Urology, Akita University School of Medicine, Akita 010-8543, Japan.
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Saito
authors.forename: Naotake
authors.initials: N
authors.lastname: Shimoda
authors.forename: Yasushiro
authors.initials: Y
authors.lastname: Terai
authors.forename: Susumu
authors.initials: S
authors.lastname: Akihama
authors.forename: Masahiro
authors.initials: M
authors.lastname: Iinuma
authors.forename: Kenji
authors.initials: K
authors.lastname: Mitsumori
authors.forename: Chikara
authors.initials: C
authors.lastname: Ohyama
authors.forename: Shigeru
authors.initials: S
authors.lastname: Satoh
authors.forename: Kazunari
authors.initials: K
authors.lastname: Sato
authors.forename: Tomonori
authors.initials: T
authors.lastname: Habuchi
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kato
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D018236:Carcinoma, Embryonal / Q000503:physiopathology / Q000601:surgery*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005298:Fertility; D006801:Humans; D008297:Male; D016609:Neoplasms, Second Primary; D009845:Oligospermia / Q000139:chemically induced; D009919:Orchiectomy / Q000379:methods*; D018239:Seminoma / Q000503:physiopathology / Q000601:surgery*; D013724:Teratoma / Q000601:surgery*; D013736:Testicular Neoplasms / Q000503:physiopathology / Q000601:surgery*; D013737:Testis / Q000502:physiology / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin